Amendment: SEC Form S-4/A filed by Black Hawk Acquisition Corporation
$BKHA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
10-Q - Black Hawk Acquisition Corp (0002000775) (Filer)
NT 10-Q - Black Hawk Acquisition Corp (0002000775) (Filer)
8-K - Black Hawk Acquisition Corp (0002000775) (Filer)
BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles and a proposed de-SPAC acquisition target for Black Hawk Acquisition Corporation (NASDAQ:BKHA, BKHAU, BKHAR)), today announced that its Board of Directors has appointed Michael Tolentino, M.D., an accomplished biotech leader with deep industry experience, as Chief Executive Officer (CEO), effective March 17, 2026. He succeeds Founder and CEO Luo Feng, Ph.D., who has been appointed Chief Scientific Officer. "Dr. Tolentino
SC 13G/A - Black Hawk Acquisition Corp (0002000775) (Subject)
SC 13G - Black Hawk Acquisition Corp (0002000775) (Subject)
SC 13G - Black Hawk Acquisition Corp (0002000775) (Subject)
BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles and a proposed de-SPAC acquisition target for Black Hawk Acquisition Corporation (NASDAQ:BKHA, BKHAU, BKHAR)), today announced that its Board of Directors has appointed Michael Tolentino, M.D., an accomplished biotech leader with deep industry experience, as Chief Executive Officer (CEO), effective March 17, 2026. He succeeds Founder and CEO Luo Feng, Ph.D., who has been appointed Chief Scientific Officer. "Dr. Tolentino